IL218317A - Use of compositions containing il-15 polypeptide and il-15 containing complexes for the preparation of medicaments for treatment of cancer - Google Patents

Use of compositions containing il-15 polypeptide and il-15 containing complexes for the preparation of medicaments for treatment of cancer

Info

Publication number
IL218317A
IL218317A IL218317A IL21831712A IL218317A IL 218317 A IL218317 A IL 218317A IL 218317 A IL218317 A IL 218317A IL 21831712 A IL21831712 A IL 21831712A IL 218317 A IL218317 A IL 218317A
Authority
IL
Israel
Prior art keywords
medicaments
polypeptide
cancer
preparation
treatment
Prior art date
Application number
IL218317A
Other languages
Hebrew (he)
Other versions
IL218317A0 (en
Original Assignee
Univ Of Connecticut Health Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37448763&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL218317(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Of Connecticut Health Center filed Critical Univ Of Connecticut Health Center
Publication of IL218317A0 publication Critical patent/IL218317A0/en
Publication of IL218317A publication Critical patent/IL218317A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
IL218317A 2005-05-17 2012-02-26 Use of compositions containing il-15 polypeptide and il-15 containing complexes for the preparation of medicaments for treatment of cancer IL218317A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68166305P 2005-05-17 2005-05-17
PCT/US2006/019403 WO2007001677A2 (en) 2005-05-17 2006-05-17 Compositions and methods for immunomodulation in an organism
US11/435,497 US8124084B2 (en) 2005-05-17 2006-05-17 Compositions and methods for immunomodulation in an organism using IL-15 and soluble IL-15Ra

Publications (2)

Publication Number Publication Date
IL218317A0 IL218317A0 (en) 2012-04-30
IL218317A true IL218317A (en) 2017-08-31

Family

ID=37448763

Family Applications (2)

Application Number Title Priority Date Filing Date
IL187317A IL187317A (en) 2005-05-17 2007-11-12 Compositions comprising il-15 and il-15ra polypeptide complexes for use in increasing immune cell proliferation
IL218317A IL218317A (en) 2005-05-17 2012-02-26 Use of compositions containing il-15 polypeptide and il-15 containing complexes for the preparation of medicaments for treatment of cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL187317A IL187317A (en) 2005-05-17 2007-11-12 Compositions comprising il-15 and il-15ra polypeptide complexes for use in increasing immune cell proliferation

Country Status (12)

Country Link
US (8) US8124084B2 (en)
EP (3) EP3263581B1 (en)
JP (3) JP5236461B2 (en)
AU (1) AU2006262711B2 (en)
CA (1) CA2608474C (en)
CY (2) CY1122925T1 (en)
IL (2) IL187317A (en)
MX (2) MX2007014474A (en)
NZ (2) NZ563263A (en)
PL (2) PL1899364T3 (en)
PT (1) PT1899364T (en)
WO (1) WO2007001677A2 (en)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ563263A (en) 2005-05-17 2010-04-30 Univ Connecticut Composition and methods for immunomodulation in an organism
EP1777294A1 (en) * 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
PL2251034T3 (en) 2005-12-02 2018-07-31 Icahn School Of Medicine At Mount Sinai Chimeric newcastle disease viruses presenting non-native surface proteins and uses thereof
BRPI0707106B1 (en) * 2006-01-13 2022-06-07 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Interleukin-15 polynucleotide expression vector and pharmaceutical composition
WO2008089144A2 (en) * 2007-01-12 2008-07-24 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Improved dna vaccination protocols
CN108948177B (en) 2007-05-11 2022-04-22 阿尔托生物科学有限公司 Fusion molecules and IL-15 variants
AU2016206235B2 (en) * 2007-06-27 2017-04-20 Novartis Ag Complexes of il-15 and il-15ralpha and uses thereof
EP2173378B1 (en) 2007-06-27 2014-03-19 Admune Therapeutics LLC Complexes of il-15 and il-15ralpha and uses thereof
EP3936122A1 (en) * 2008-11-24 2022-01-12 Massachusetts Institute Of Technology Methods and compositions for localized agent delivery
WO2010071836A1 (en) 2008-12-19 2010-06-24 Inserm Il-15 mediated nk and t cell maturation
US8871191B2 (en) * 2009-08-14 2014-10-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of IL-15 preparations to treat lymphopenia
CN102821790A (en) * 2009-09-14 2012-12-12 宾夕法尼亚大学托管会 Vaccines and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same
EP2614151B1 (en) 2010-09-08 2019-07-24 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Interleukin 15 as selectable marker for gene transfer in lymphocytes
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
US8507222B2 (en) 2010-09-21 2013-08-13 Altor Bioscience Corporation Multimeric IL-15 soluble fusion molecules and methods of making and using same
PT2665486T (en) 2011-01-18 2020-03-30 Bioniz Llc Compositions and mehthods for modulating gamma-c-cytokine activity
WO2015089217A2 (en) 2013-12-10 2015-06-18 Bionz, Llc Methods of developing selective peptide antagonists
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
JP6359019B2 (en) * 2012-10-24 2018-07-18 ノバルティス アーゲー IL-15Rα type, cells expressing IL-15Rα type, and therapeutic use of IL-15Rα and IL-15 / IL-15Rα complex
MA38406B1 (en) 2013-03-14 2020-03-31 Icahn School Med Mount Sinai Newcastle disease viruses and their uses
TWI654206B (en) 2013-03-16 2019-03-21 諾華公司 Treatment of cancer with a humanized anti-CD19 chimeric antigen receptor
US11401312B2 (en) 2013-04-19 2022-08-02 Cytune Pharma Cytokine derived treatment with reduced vascular leak syndrome
KR102095700B1 (en) 2013-05-14 2020-04-01 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Human application of engineered chimeric antigen receptor (car) t-cells
PL3444271T3 (en) 2013-08-08 2022-03-07 Cytune Pharma Il-15 and il-15ralpha sushi domain based modulokines
PL3030262T3 (en) 2013-08-08 2020-07-27 Cytune Pharma Combined pharmaceutical composition
WO2015048498A2 (en) 2013-09-27 2015-04-02 Massachusetts Institute Of Technology Carrier-free biologically-active protein nanostructures
GB201317355D0 (en) * 2013-10-01 2013-11-13 Epistem Ltd Mutation Analysis
EP3461331A1 (en) * 2013-10-15 2019-04-03 Regeneron Pharmaceuticals, Inc. Humanized il-15 animals
RU2672055C2 (en) * 2013-11-01 2018-11-09 Йейл Юниверсити Modular particles for immunotherapy
CN113637692A (en) 2014-01-15 2021-11-12 卡德门企业有限公司 Immunomodulator
AU2015222685A1 (en) 2014-02-27 2016-09-08 Viralytics Limited Combination method for treatment of cancer
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
ES2876263T3 (en) 2014-04-07 2021-11-12 Novartis Ag Cancer treatment using anti-cd19 chimeric antigen receptor
US20150307620A1 (en) * 2014-04-16 2015-10-29 University Of Connecticut Linked immunotherapeutic agonists that costimulate multiple pathways
CN106659775B (en) 2014-06-30 2021-08-06 阿尔托生物科学有限公司 IL-15-based molecules, methods and uses thereof
SG11201700416TA (en) 2014-07-21 2017-02-27 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
CN106687483B (en) 2014-07-21 2020-12-04 诺华股份有限公司 Treatment of cancer using humanized anti-BCMA chimeric antigen receptors
EP3174974B1 (en) 2014-07-29 2020-05-20 Novartis AG Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions
MA40094B1 (en) * 2014-08-06 2022-05-31 Univ Miami Interleukin-2/interleukin-2 alpha receptor fusion proteins and methods of use
WO2016025880A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using gfr alpha-4 chimeric antigen receptor
EP3712171A1 (en) 2014-08-19 2020-09-23 Novartis AG Treatment of cancer using a cd123 chimeric antigen receptor
DK3194443T3 (en) 2014-09-17 2021-09-27 Novartis Ag TARGETING OF CYTOTOXIC CELLS WITH CHIMARY RECEPTORS IN CONNECTION WITH ADOPTIVE IMMUNTERAPHY
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
JP6961490B2 (en) 2015-04-08 2021-11-05 ノバルティス アーゲー CD20 therapy, CD22 therapy, and combination therapy with CD19 chimeric antigen receptor (CAR) expressing cells
US20180298068A1 (en) 2015-04-23 2018-10-18 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
EP3334417A4 (en) 2015-08-12 2019-07-17 Massachusetts Institute of Technology Cell surface coupling of nanoparticles
EP3344575B1 (en) 2015-09-04 2020-04-15 SQZ Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
HUE056544T2 (en) 2015-10-09 2022-02-28 Bioniz Llc Modulating gamma - c -cytokine activity
US20170157215A1 (en) * 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
JP7082055B2 (en) 2015-12-22 2022-06-07 ノバルティス アーゲー Antibodies to Mesothelin Chimeric Antigen Receptor (CAR) and PD-L1 Inhibitors for Combined Use in Anticancer Treatment
KR20180095713A (en) 2016-01-11 2018-08-27 루비우스 테라퓨틱스, 아이엔씨. Compositions and methods related to multimodal therapeutic cell systems for immunological indications
CN109153714A (en) 2016-03-04 2019-01-04 诺华股份有限公司 Express the cell and application thereof of multiple Chimeric antigen receptor (CAR) molecule
AU2017244108B2 (en) 2016-03-29 2021-03-18 University Of Southern California Chimeric antigen receptors targeting cancer
US20190117690A1 (en) * 2016-04-06 2019-04-25 The University State Of America As Represented By The Secretary Of The Department Of Health And Hum Use of heterodimeric il-15 in adoptive cell transfer
GB2549287B (en) 2016-04-11 2019-07-24 Self Energising Coupling Co Ltd Fluid coupling with cam and follower controlled securing means
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
AU2017268399B2 (en) 2016-05-18 2023-01-12 Modernatx, Inc. mRNA combination therapy for the treatment of cancer
CA3029813A1 (en) 2016-06-13 2017-12-21 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
CA3031542A1 (en) 2016-07-20 2018-01-25 University Of Utah Research Foundation Cd229 car t cells and methods of use thereof
AU2017341047A1 (en) 2016-10-07 2019-05-02 Novartis Ag Chimeric antigen receptors for the treatment of cancer
SG11201903302UA (en) 2016-10-14 2019-05-30 Xencor Inc Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
CA3200275A1 (en) 2016-10-21 2018-04-26 Nantcell, Inc. Multimeric il-15-based molecules
KR20190102259A (en) 2017-01-10 2019-09-03 인트렉손 코포레이션 Regulation of Polypeptide Expression Through a Novel Gene Switch Expression System
US20200237874A1 (en) 2017-01-20 2020-07-30 Novartis Ag Combination therapy for the treatment of cancer
KR20190105584A (en) 2017-01-20 2019-09-17 노파르티스 아게 Combination Therapy for Cancer Treatment
BR112019018915A2 (en) 2017-03-15 2020-04-14 Pandion Therapeutics Inc targeted immunotolerance
WO2018195339A1 (en) 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
CN111010866A (en) 2017-05-24 2020-04-14 潘迪恩治疗公司 Targeted immune tolerance
EP3630132A1 (en) 2017-06-02 2020-04-08 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
WO2018229706A1 (en) 2017-06-16 2018-12-20 Novartis Ag Combination therapy for the treatment of cancer
US20220225597A1 (en) 2017-06-29 2022-07-21 Juno Therapeutics, Inc. Mouse model for assessing toxicities associated with immunotherapies
MA49517A (en) 2017-06-30 2020-05-06 Xencor Inc TARGETED HETERODIMERIC FC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND AREAS OF ANTIGEN BINDING
WO2019019998A1 (en) 2017-07-25 2019-01-31 江苏恒瑞医药股份有限公司 Il-15 protein complex pharmaceutical composition and uses thereof
US11524033B2 (en) 2017-09-05 2022-12-13 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
KR20200074997A (en) 2017-11-01 2020-06-25 주노 쎄러퓨티크스 인코퍼레이티드 Antibodies and chimeric antigen receptors specific for B-cell maturation antigens
EP3703750A1 (en) 2017-11-01 2020-09-09 Juno Therapeutics, Inc. Chimeric antigen receptors specific for b-cell maturation antigen and encoding polynucleotides
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
KR20200110745A (en) 2017-12-15 2020-09-25 주노 쎄러퓨티크스 인코퍼레이티드 Anti-CCT5 binding molecule and method of use thereof
AU2019213843A1 (en) 2018-02-02 2020-08-20 Aduro Biotech Inc. Combination of STING agonist and IL-15/IL15-Ra for the treatment of cancer
RU2020128440A (en) 2018-02-28 2022-03-28 Пфайзер Инк. IL-15 OPTIONS AND THEIR APPLICATIONS
PE20210313A1 (en) 2018-03-28 2021-02-12 Bristol Myers Squibb Co INTERLEUKIN-2 FUSION PROTEINS / INTERLEUKIN-2 ALPHA RECEPTOR AND METHODS OF USE
JP2021520829A (en) 2018-04-18 2021-08-26 ゼンコア インコーポレイテッド TIM-3 targeted heterodimer fusion protein containing IL-15 / IL-15RA Fc fusion protein and TIM-3 antigen binding domain
CN112867734A (en) 2018-04-18 2021-05-28 Xencor股份有限公司 PD-1 targeting heterodimeric fusion proteins comprising an IL-15/IL-15Ra Fc fusion protein and a PD-1 antigen binding domain and uses thereof
US20210047405A1 (en) 2018-04-27 2021-02-18 Novartis Ag Car t cell therapies with enhanced efficacy
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
TW202016139A (en) 2018-06-13 2020-05-01 瑞士商諾華公司 Bcma chimeric antigen receptors and uses thereof
WO2020069405A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
EP3856782A1 (en) 2018-09-28 2021-08-04 Novartis AG Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
WO2020077276A2 (en) 2018-10-12 2020-04-16 Xencor, Inc. Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
EP3873937A2 (en) 2018-11-01 2021-09-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
WO2020092848A2 (en) 2018-11-01 2020-05-07 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
KR20210104713A (en) 2018-11-16 2021-08-25 주노 쎄러퓨티크스 인코퍼레이티드 Engineered T-cell dosing methods for treatment of B-cell malignancies
EP3883611A4 (en) * 2018-11-19 2023-02-22 Dana-Farber Cancer Institute, Inc. Use of ire1alpha-xbp1 signaling pathway biomarkers for modulating immune responses
JP2022513685A (en) 2018-11-30 2022-02-09 ジュノー セラピューティクス インコーポレイテッド Methods for Treatment with Adoptive Cell Therapy
EP3897853A1 (en) 2018-12-20 2021-10-27 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
CN113365660A (en) 2019-01-29 2021-09-07 朱诺治疗学股份有限公司 Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase-like orphan receptor 1(ROR1)
CA3131701A1 (en) 2019-02-28 2020-09-03 Sqz Biotechnologies Company Delivery of biomolecules to pbmcs to modify an immune response
MX2021014178A (en) 2019-05-20 2022-01-04 Pandion Operations Inc Madcam targeted immunotolerance.
MX2022003192A (en) 2019-09-18 2022-04-11 Novartis Ag Nkg2d fusion proteins and uses thereof.
TW202128757A (en) 2019-10-11 2021-08-01 美商建南德克公司 Pd-1 targeted il-15/il-15ralpha fc fusion proteins with improved properties
AU2020407233A1 (en) 2019-12-20 2022-08-18 Regeneron Pharmaceuticals, Inc. Novel IL2 agonists and methods of use thereof
WO2021156720A1 (en) 2020-02-05 2021-08-12 Novartis Ag Cho cell expressing il-15 heterodimers
WO2021202354A1 (en) * 2020-03-30 2021-10-07 Proviva Therapeutics (Hong Kong) Limited Il-2/il-15 compositions and methods of use thereof
BR112022020333A2 (en) 2020-04-10 2022-11-22 Juno Therapeutics Inc METHODS AND USES RELATED TO CELL THERAPY DESIGNED WITH A CHIMERIC ANTIGEN RECEPTOR THAT TARGETS B CELL MATURATION ANTIGEN
EP4138782A1 (en) 2020-04-22 2023-03-01 Novartis AG Pharmaceutical compositions and pharmaceutical products of heterodimeric human interleukin-15 (hetil-15)
US20230322881A1 (en) 2020-08-31 2023-10-12 Gi Cell, Inc. Fusion protein including il15 protein, il15 receptor alpha protein, fc domain, and il2 protein, and use thereof
AU2021378316A1 (en) 2020-11-13 2023-06-01 Novartis Ag Combination therapies with chimeric antigen receptor (car)-expressing cells
WO2022125694A1 (en) * 2020-12-09 2022-06-16 Asher Biotherapeutics, Inc. Fusions of interleukin polypeptides with bispecific antigen binding molecules for modulating immune cell function
CA3220418A1 (en) 2021-06-23 2022-12-29 Guy Luc Michel De Martynoff Interleukin 15 variants
US20230151095A1 (en) 2021-11-12 2023-05-18 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
WO2023086642A2 (en) * 2021-11-15 2023-05-19 City Of Hope Engineering or inducing pdgf and/or pdgfr signaling to enhance nk cell therapy
WO2023250400A1 (en) 2022-06-22 2023-12-28 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
US20240041929A1 (en) 2022-08-05 2024-02-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (en) 1978-01-06 1979-08-03 David Bernard DRYER FOR SCREEN-PRINTED SHEETS
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
DE3751873T2 (en) 1986-04-09 1997-02-13 Genzyme Corp Genetically transformed animals that secrete a desired protein in milk
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU4308689A (en) 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
ES2096590T3 (en) 1989-06-29 1997-03-16 Medarex Inc BI-SPECIFIC REAGENTS FOR AIDS THERAPY.
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ATE139258T1 (en) 1990-01-12 1996-06-15 Cell Genesys Inc GENERATION OF XENOGENE ANTIBODIES
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (en) 1990-07-10 2000-04-17 Cambridge Antibody Tech Process for producing specific binding pair elements
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5612205A (en) 1990-08-29 1997-03-18 Genpharm International, Incorporated Homologous recombination in mammalian cells
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DK0564531T3 (en) 1990-12-03 1998-09-28 Genentech Inc Enrichment procedure for variant proteins with altered binding properties
ES2287206T3 (en) 1991-03-01 2007-12-16 Dyax Corporation PROCESS FOR THE DEVELOPMENT OF MINI-PROTEINS OF UNION.
IE921169A1 (en) 1991-04-10 1992-10-21 Scripps Research Inst Heterodimeric receptor libraries using phagemids
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
DE4122599C2 (en) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid for screening antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
EP0652950B1 (en) 1992-07-24 2007-12-19 Amgen Fremont Inc. Generation of xenogeneic antibodies
JP3095175B2 (en) 1992-11-13 2000-10-03 アイデック ファーマシューティカルズ コーポレイション Therapeutic use of chimeric and radiolabeled antibodies against human B lymphocyte restricted differentiation antigen for the treatment of B cell lymphoma
US5552303A (en) 1993-03-08 1996-09-03 Immunex Corporation DNA encoding epithelium-derived T-cell factor
US5574138A (en) 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US6063911A (en) 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
US5858350A (en) * 1993-12-01 1999-01-12 Marine Polymer Technologies Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system
CA2186747C (en) 1994-04-06 2009-01-27 Kenneth H. Grabstein Interleukin-15
US6548065B1 (en) 1994-05-06 2003-04-15 Immunex Corporation Interleukin-15 receptors
US5591630A (en) 1994-05-06 1997-01-07 Immunex Corporation Monoclonal antibodies that bind interleukin-15 receptors
US20020127201A1 (en) 1994-07-01 2002-09-12 Dana-Farber Cancer Institute. Methods for inhibiting T cell responses by manipulating a common cytokine receptor gamma-chain
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US7008624B1 (en) * 1995-02-22 2006-03-07 Immunex Corporation Antagonists of interleukin-15
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JP4312259B2 (en) 1995-04-27 2009-08-12 アムジェン フレモント インク． Human antibodies derived from immunized XenoMouse
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5660824A (en) 1995-05-24 1997-08-26 Grabstein; Kenneth H. Muscle trophic factor
DE19608813C2 (en) * 1996-03-07 1998-07-02 Angewandte Gentechnologie Syst Conjugate for influencing interactions between proteins
US6001973A (en) 1996-04-26 1999-12-14 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
US6451308B1 (en) 1996-04-26 2002-09-17 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
DE69810091T2 (en) 1997-02-21 2003-10-09 Vlaams Interuniv Inst Biotech USE OF INTERLEUKIN-15
US6787132B1 (en) * 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
US20040170604A1 (en) * 1998-07-06 2004-09-02 Tosoh Corporation IL-6 receptor IL-6 direct fusion protein
JP4524816B2 (en) * 1998-07-06 2010-08-18 東ソー株式会社 IL-6 receptor / IL-6 direct fusion protein
AU2001259253A1 (en) 2000-04-26 2001-11-07 National Jewish Medical And Research Center Product and process for regulation of t cell responses
IL154925A0 (en) 2000-09-14 2003-10-31 Beth Israel Hospital Modulation of il-2 and il-15-mediated t cell responses
US7638604B2 (en) * 2001-02-23 2009-12-29 Genetics Institute, Llc Monoclonal antibodies against interleukin-22
GB0209893D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
CA2510309C (en) 2002-12-16 2014-09-16 Liyange P. Perera Recombinant vaccine viruses expressing il-15 and methods of using the same
DE10260805A1 (en) 2002-12-23 2004-07-22 Geneart Gmbh Method and device for optimizing a nucleotide sequence for expression of a protein
US20040229330A1 (en) * 2003-02-27 2004-11-18 Bayer Pharmaceuticals Corporation Integrated method for capture and purification of tagged proteins
EP1671643A1 (en) 2003-09-08 2006-06-21 Intellectual Property Consulting Inc. Medicinal composition for treating chronic hepatitis c
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
ATE516305T1 (en) 2004-02-27 2011-07-15 Inst Nat Sante Rech Med IL-15 BINDING SITE FOR IL-15-RALPHA AND SPECIFIC IL-15 MUTANTS ACTING AS AGONISTS/ANTAGONISTS
WO2006017853A2 (en) 2004-08-11 2006-02-16 Beth Israel Deaconess Medical Center, Inc. Mutant interleukin-15-containing compositions and suppression of an immune response
CA2583274A1 (en) * 2004-10-05 2007-02-15 Ochsner Clinic Foundation Enhancement of b cell proliferation by il-15
US20060165668A1 (en) * 2004-12-10 2006-07-27 Liu Linda N Genetically modified tumor cells as cancer vaccines
CA2590778A1 (en) 2004-12-13 2006-06-22 Cytos Biotechnology Ag Il-15 antigen arrays and uses thereof
RU2007134368A (en) 2005-02-15 2009-03-27 Новартис Вэксинес Энд Дайэгностикс Инк. (Us) METHODS FOR TREATING LYMPHOMAS USING A COMBINATION OF CHEMOTHERAPEUTIC AND IL-2, AND, NOT MANDATORY, ANTIBODY ANTI-CD20
US20060257361A1 (en) 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
NZ563263A (en) 2005-05-17 2010-04-30 Univ Connecticut Composition and methods for immunomodulation in an organism
EP1777294A1 (en) * 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
US20070160578A1 (en) 2005-12-14 2007-07-12 The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes
BRPI0707106B1 (en) 2006-01-13 2022-06-07 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Interleukin-15 polynucleotide expression vector and pharmaceutical composition
EP1987065A4 (en) 2006-02-16 2010-01-20 Nascent Biolog Inc Methods for improving immune function and methods for prevention or treatment of disease in a mammalian subject
WO2008089144A2 (en) 2007-01-12 2008-07-24 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Improved dna vaccination protocols
CN108948177B (en) 2007-05-11 2022-04-22 阿尔托生物科学有限公司 Fusion molecules and IL-15 variants
EP2173378B1 (en) 2007-06-27 2014-03-19 Admune Therapeutics LLC Complexes of il-15 and il-15ralpha and uses thereof
US8871191B2 (en) 2009-08-14 2014-10-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of IL-15 preparations to treat lymphopenia
US8507222B2 (en) 2010-09-21 2013-08-13 Altor Bioscience Corporation Multimeric IL-15 soluble fusion molecules and methods of making and using same
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
RU2020128440A (en) 2018-02-28 2022-03-28 Пфайзер Инк. IL-15 OPTIONS AND THEIR APPLICATIONS

Also Published As

Publication number Publication date
CY1122925T1 (en) 2021-10-29
WO2007001677A3 (en) 2007-07-05
EP3263581A1 (en) 2018-01-03
JP5707377B2 (en) 2015-04-30
US20160347818A1 (en) 2016-12-01
JP2015007086A (en) 2015-01-15
US8124084B2 (en) 2012-02-28
WO2007001677A2 (en) 2007-01-04
JP2013067632A (en) 2013-04-18
CY1123763T1 (en) 2022-05-27
PL3263581T3 (en) 2021-05-04
PL1899364T3 (en) 2020-08-24
US20150093357A1 (en) 2015-04-02
CA2608474C (en) 2019-11-12
US9969790B2 (en) 2018-05-15
AU2006262711A1 (en) 2007-01-04
NZ581779A (en) 2011-09-30
JP5918817B2 (en) 2016-05-18
US9365630B2 (en) 2016-06-14
US11008378B2 (en) 2021-05-18
CA2608474A1 (en) 2007-01-04
US20180298079A1 (en) 2018-10-18
IL187317A0 (en) 2008-04-13
US9932387B2 (en) 2018-04-03
EP3263581B1 (en) 2020-11-04
US10464993B2 (en) 2019-11-05
US20200291091A1 (en) 2020-09-17
IL218317A0 (en) 2012-04-30
MX339305B (en) 2016-05-19
WO2007001677A9 (en) 2007-08-23
EP1899364A4 (en) 2009-05-20
EP1899364B1 (en) 2020-02-19
US8940288B2 (en) 2015-01-27
MX2007014474A (en) 2008-02-07
EP1899364A2 (en) 2008-03-19
AU2006262711B2 (en) 2013-01-31
US20150139945A1 (en) 2015-05-21
JP2008545397A (en) 2008-12-18
US20060263857A1 (en) 2006-11-23
US20120177598A1 (en) 2012-07-12
US20160333067A1 (en) 2016-11-17
US9371368B2 (en) 2016-06-21
EP3805245A1 (en) 2021-04-14
JP5236461B2 (en) 2013-07-17
NZ563263A (en) 2010-04-30
PT1899364T (en) 2020-05-20
IL187317A (en) 2016-12-29

Similar Documents

Publication Publication Date Title
IL218317A (en) Use of compositions containing il-15 polypeptide and il-15 containing complexes for the preparation of medicaments for treatment of cancer
EP1814909A4 (en) Use of aimp2dx2 for the diagnosis and treatment of cancer
IL177283A (en) Pyrazolopyrimidine compounds, use thereof for the preparation of medicaments and pharmaceutical compositions comprising same
HK1105886A1 (en) Pharmaceutical compositions comprising l-733060 for use in the treatment of cancer tumours l-733060
IL191984A0 (en) Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents for the treatment of cancer
GB0522311D0 (en) Pharmaceutical compositions for the treatment of pain
IL185462A0 (en) New pharmaceutical compositions useful in the treatment of pain
PL1765391T3 (en) Bacterial compositions for the treatment of cancer
IL186662A (en) Use of bis(thiohydrazide amide) for the preparation of a medicament for treating a human with cancer
ZA200707638B (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
EP1985302A4 (en) Medicament for treatment of tumor and the use thereof
EP1812596A4 (en) Treatment of cancer and compositions
IL164896A (en) Pharmaceutical compositions comprising immunoconjugates for the treatment of tumors
PL1799188T3 (en) Use of peptides as an antioxidant agent for the preparation of a cosmetic and/or pharmaceutical composition
IL178939A (en) Dual and triple combinations suitable for the synergistic treatment of breast cancer, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments or as medicaments for the treatment of breast cancer
EP1768685A4 (en) Cosmetic compositions and methods comprising rhodiola rosea
HK1100484A1 (en) Application of n-butylidenephthalide in preparing cancer treatment medication
IL196606A (en) Use of escin for the manufacture of pharmaceutical preparations and pharmaceutical compositions comprising escin for treating diseases
AU2006251169A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
AU2006251167A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
HK1111599A1 (en) Pharmaceutical compositions for the treatment of cellulite
EP1904088A4 (en) Compositions and methods for the treatment of cancer
HUP0500199A2 (en) Pharmaceutical composition comprising arsenite for the treatment of malignancy
EP1757282A4 (en) The use of kauranes compounds in the manufacture of medicament
EP1797430A4 (en) Methods and compositions for the diagnosis and treatment of cancer

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed